Pharmaceutical investigators are searching for preclinical models closely resembling the original cancer and predicting clinical outcome. This study compares drug response of three in vitro 3D-drug screening models with different complexity.
Introduction
Preclinical cancer models predicting clinical treatment outcome are urgently required in early drug development. Currently much effort is being spent on the development of refined preclinical models, in vitro as well as in vivo, to bridge the gap between successful preclinical studies and success in clinical trials.
One of the key players impacting drug efficacy is the tumor microenvironment (Hanahan and Weinberg, 2011) . A number of factors such as hypoxia and acidosis, complex interactions between cancer cells and different stromal cell types as well as the extracellular matrix and various soluble factors have been associated with both drug resistance and sensitization. In addition, the tumor microenvironment has been previously associated with changes in biomarker expression on cancer cells, which is important for patient stratification in targeted therapy. Stromal cell types that are interesting especially with regard to treatment efficacy include the tumor endothelial cells, the tumor infiltrating lymphocytes (TILs), the tumor associated macrophages (TAMs) and the tumor associated fibroblasts (TAFs, CAFs). All these cell types are targets of new treatment strategies aimed at the tumor stroma (Correia and Bissell, 2012; Hanahan and Coussens, 2012; Zhang and Liu, 2013; Santoni et al., 2013; McMillin et al., 2013; Kyi and Postow, 2014) .
The complexity, heterogeneity, plasticity and diversity of the human tumor microenvironment cannot be replicated in preclinical 2D tumor cell line models, leaving these inaccurate for deductions regarding clinical response. Similarly, despite the remarkable progress in generation of humanized mouse models, mouse biology does not allow for an authentic model of human tumors to be generated (Das Thakur et al., 2014; Hayes et al., 2014; Malaney et al., 2014) . The increasing research on the different cellular subtypes in the tumor micromilieu, which communicate directly and indirectly with the cancer cells, has led to the development of more complex preclinical in vitro models in early drug development (Alépée et al., 2014; Lovitt et al., 2014; Xu et al., 2014) .
Using the example of human colorectal cancer in the present study, 3D spheroid models of different complexity regarding cellular composition were generated and the impact of clinically relevant drug combinations, targeted and non-targeted, was evaluated in each model.
Materials and methods

Cell lines and culture conditions
Five colon cancer cell lines were used for the initial experiments, namely Caco-2 (ATCC Nr. HTB-37), DLD-1 (ATCC Nr. CCL-221), COLO 205 (ATCC Nr. CCL-222), and . Cell lines were cultivated in RPMI 1640 (PAN Biotech, Aidenbach, Germany) supplemented with 10% FBS (PAN Biotech, Aidenbach, Germany) and 2 mM L-Glutamin (PAN Biotech, Aidenbach, Germany). Primary cancer associated fibroblasts of colorectal origin were cultured in MEM (PAN Biotech, Aidenbach, Germany) supplemented with 20% FBS and 0.26 M Amphotericin B (Biochrom, Berlin, Germany). DMEM/F12 medium (PAN Biotech, Aidenbach, Germany) supplemented with 10% FBS (PAN Biotech, Aidenbach, Germany), 2× MEM non-essential amino acid solution (PAN Biotech, Aidenbach, Germany), 2× MEM vitamin solution (PAN Biotech, Aidenbach, Germany), 0.14 mM Ampicillin (ratiopharm, Ulm, Germany), 0.26 M Amphotericin B (Biochrom, Berlin, Germany), 7.54 M Ciprofloxacin (Fresenius Kabi, Bad Homburg, Germany), 50 g/ml Gentamicin (ratiopharm, Ulm, Germany) and 0.29 mM Metronidazol (B. Braun Melsungen, Melsungen, Germany) was used for primary colorectal cancer cells isolated from tissue samples. All cells were incubated under standard culture conditions (37 • C, 5% CO 2 ). Expansion and passaging of adherent cells were performed by detachment with a 0.05% trypsin/0.53 mM EDTA solution (PAN, Aidenbach, Germany). To determine cell number and cell viability, 0.4% trypan blue solution (Sigma-Aldrich, Steinheim, Germany) was used in a ratio of 1:1 for the trypan blue exclusion test.
Tissue and blood samples
The study was conducted according to the Declaration of Helsinki Principles and was approved by the local ethics committee. Tissue and blood samples were obtained with the informed consent of the three healthy donors (blood) and the 16 cancer patients (tissue). Samples were handled and stored according to standard bio banking guidelines with special focus on short ischemic times of less than 30 min. Tissue samples were used for fibroblast isolation as well as spheroid preparation and peripheral blood mononuclear cells (PBMCs) were isolated from donated blood samples.
Isolation of PBMCs
PBMCs were isolated according to the standard Ficoll density gradient centrifugation method (Mallone et al., 2011) . Briefly, lithium heparin blood samples (15 ml) were filtered through a 100 m cell strainer and the strainer washed once using DPBS (PAN Biotech, Aidenbach, Germany) to obtain a final volume of 30 ml. Two separate tubes were prepared with Ficoll-Paque Plus (GE Healthcare, Little Chalfont, UK) and overlaid with the blood/DPBS mixture in a 1:1 ratio. Following centrifugation (30 min, 497 g, 21 • C) the interphase was transferred to a new tube and washed with primary cell culture medium. After determination of the viability the isolated PBMCs were resuspended in primary cell culture medium and used for homotypic and co-culture experiments.
Isolation of primary cancer-associated fibroblasts of colorectal origin
Primary human fibroblasts were isolated similar to Herrera et al. (2013b) . Briefly, fresh primary colorectal tumor samples were mechanically and enzymatically digested using collagenase (Sigma-Aldrich, Steinheim, Germany). The single cell suspension was transferred into 1% sterile gelatin biocoated cell culture flasks and cultured under standard conditions as described above. The medium was renewed twice a week to remove tissue debris. For experiments fibroblasts between passages three and eight were used.
2.5. Spheroid preparation 2.5.1. The tumor cell line spheroid model Spheroids were generated as previously described (Mayer et al., 2001) . Briefly, monolayer cultures of tumor cell lines were allowed to reach a minimal confluency of 90% for spheroid culture. The viability and the cell number of the cell suspensions used for spheroid culture were assessed. Only cell suspensions with a viability of at least 90% were used for spheroid culture. For spheroid formation, 5 × 10 4 vital cells per well in either 100 l or 50 l per well were seeded in a 96 well microtiter plate and cultured for 48 h at standard culture conditions as mentioned above.
3D co-culture of tumor cell lines with stromal cells
For co-culture experiments with fibroblasts isolated from primary colorectal cancer samples, a cell suspension consisting of an equal number of tumor cells and primary cancer-associated fibroblasts of colorectal origin were used for spheroid formation. Vital cells were seeded at a density of 5 × 10 4 per well.
Co-culture experiments with PBMCs were performed using homotypic tumor cell line spheroids. 5 × 10 4 freshly isolated PBMCs were added per well to pre-formed spheroids 48 h after tumor cell seeding simultaneously with the drugs used for the experiments.
Heterotypic spheroids from cancer tissue
Surgical tissue resectates were dissected and cancer tissue samples provided by pathologists of the University Hospital LMU, Germany. After macroscopic removal of the non-tumorous tissue and the performance of several washing steps, the tumor tissue was mechanically and enzymatically digested with Liberase TM (Roche Applied Science, Basel, Switzerland) according to the manufacturer's protocol in FBS free medium until the extracellular matrix was almost entirely digested and all cell types were isolated to obtain a single cell suspension. The digestion progress was microscopically monitored every 30 min. The enzymatic reaction was terminated by adding 10% FBS to the cell suspension. Most importantly, all the different cell types given in the individual cancer tissue were retained. No cell depletion or enrichment step was performed. The cell suspension was washed twice with primary cell culture medium as described above and the cell number and viability assessed before the cells were directly used for spheroid formation. A minimal vitality of 80% was required for spheroid culture (Gaedtke et al., 2007) .
Cancer therapy
After 48 h of spheroid formation, chemotherapeutic agents and molecular drugs were administered to the spheroids in clinically relevant combinations at the peak plasma concentrations as published in dose finding phase I clinical trials (FO = 5-fluorouracil + oxaliplatin, FI = 5-fluorouracil + SN38 (active metabolite of irinotecan), FOC = FO + Cetuximab, FIC = FI + Cetuximab) ( Table 1 ). The drugs were allowed to take effect for a total of 72 h. Chemotherapeutics and the antibodies were obtained from the pharmacy of the University Hospital LMU (Munich, Germany). Vorinostat and Everolimus were bought from Selleck Chemicals (Houston, TX, USA) and SN38 was obtained from Sigma-Aldrich (Steinheim, Germany). Medium and solvent controls were included in each experiment; solvent amount was adapted to the treatment combination with the highest vehicle proportion in each experiment.
Determination of cell viability following treatment
The viability of the treated tumor cell line spheroids was assessed using a solution of 3.9 mM CellTiter 96 ® AQ ueous MTS Reagent Powder (Promega, Fitchburg, WI, USA) and 0.14 mM Phenazine methosulfate (Sigma-Aldrich Steinheim, Germany) in DPBS (PAN Biotech, Aidenbach, Germany). The solution was added to the spheroids following 72 h of treatment in a ratio of 1:5 (one volume part reagent to five volume parts well content) and incubated at the culture conditions mentioned above for 6 h. The absorption of the well content was measured using a Tecan Ultra 384 multiplate reader (Tecan, Crailsheim, Germany) at 492 nm using 650 nm as reference wavelength. The cell viability of the spheroids generated from cancer tissue was measured by CellTiterGlo ® Luminescent Cell Viability Assay (Promega, Fitchburg, WI, USA) according to manufacturer's protocol 72 h after drug administration with a Tecan Ultra 384 multiplate reader (Tecan, Crailsheim, Germany).
Data analysis and statistics
Relative treatment efficacy was expressed as percent of the appropriate solvent control. To evaluate the cellular interaction in the co-culture models, expected results were calculated as reference. Under the assumption that no cellular interaction occurred in the co-culture systems, the theoretical cellular inhibition was calculated as the mean of the cell viability results of each homotypic culture model. For statistical analysis the Student's t-test was conducted using SPSS Statistics version 22 (IBM, Ehningen, Germany). p-Values <0.05 were considered significant.
Results and discussion
The tumor cell line spheroid model
Five human colon cancer cell lines were analyzed in the homotypic tumor cell line spheroid model to assess their respective response to the two standard chemotherapies in colorectal cancer (CRC) 5-fluorouracil (5-FU) combined with either oxaliplatin (FO) or irinotecan (FI). Caco-2 cell line spheroids were found sensitive to both standard chemotherapies showing a higher response to FO compared to FI. DLD-1 and COLO 205 cell line spheroids were identified as partially sensitive to FO and FI to the same extent, while HT29 and HCT-116 cell line spheroids were each resistant to both standard chemotherapies (Table 2 ). In addition, Cetuximab combination therapy approved for the treatment of advanced CRC was considered Labianca et al., 2013) . Although induction of ADCC by Cetuximab is not possible in this experimental setup, metabolic inhibition of cancer cells should be possible due to less EGFR signaling. Combination therapy of Cetuximab with both FO and FI each showed an increase in the treatment response in Caco-2 and slightly in DLD-1 cell line spheroids, while no impact was observed in COLO 205 spheroids. The treatment resistance observed earlier in HT-29 and HCT-116 spheroids was not lessened through the addition of Cetuximab treatment (Table 2 ). No evident relationship between benefit from Cetuximab therapy and KRAS gene mutation status of the cancer cells was observed although both wild type and the G13D mutated KRAS gene have been shown to result in a successful Cetuximab treatment (De Roock et al., 2010) (Table 3) .
The apparent lack of correlation between Cetuximab efficacy in the tumor cell line model in vitro and KRAS status of the cell lines used resembles the clinical response rate of current clinical trials with CRC patients (Sorich et al., 2014) . A reason for this missing relation might also be the inability of a homotypic cell line model to induce antibody-dependent cellular cytotoxicity (ADCC). This fact, and reports that the human tumor microenvironment seems to have a major impact on drug response of cancer cells (Correia and Bissell, 2012; Kharaishvili et al., 2014) , indicates that reliable deductions to clinical response rates are only possible to a limited extent with this model. While the 3D model is standardized and easily reproducible, the gap between in vitro treatment efficacy and clinical response remains. Thus, treatment experiments were performed with mixed cancer spheroid cultures to study the effect of the tumor microenvironment mediated by either the immune cells (Mitchem et al., 2013; Chanmee et al., 2014) or the fibroblasts (Fang et al., 2014; Kharaishvili et al., 2014) on treatment efficacy in vitro.
3.2. Co-culture experiments of the tumor cell line spheroid model with PBMCs
Homotypic Caco-2 and DLD-1 tumor spheroids were cocultured with freshly isolated PBMCs. The immune cells attached to the spheroid hull after introduction to the culture system ( Fig. 1A and B) . Chemotherapies were effective to the same extent against homotypic Caco-2 spheroids and PBMCs alone in single cell suspension culture. In both culture systems FO inhibited cellular viability more than FI, and in addition FOC was slightly more effective than FO. The only difference between both homotypic models regarding response to chemotherapy was observed in the efficacy of FIC compared to FI. While the addition of Cetuximab to FI reduced cell viability in the tumor spheroid model, PBMCs did not react differently (Fig. 2A) . The only experimental result in the coculture model differing from the calculated co-culture results was a slight induction of resistance to FO and FOC with no effect on their relative response compared to each other. The reduced sensitivity to FIC therapy observed in the co-culture system is a result of the large difference in reactivity between the tumor spheroids and the PBMCs but not a true co-culture effect since the experimentally assessed treatment efficacy of the co-culture model only differed negligibly from the expected response without cellular interaction ( Fig. 2A) . The DLD-1 spheroids were less sensitive to FO therapy compared to Caco-2 spheroids and no difference between sensitivity to FO and FI were observed. While the addition of Cetuximab to FO had no beneficial effect, a slightly improved response to FIC was observed in homotypic DLD-1 spheroids. The PBMC suspension cultures reacted similar to the earlier experiment with one exception, FIC was superior to FI regarding metabolic inhibition. As already observed for Caco-2 spheroids plus PBMCs, the co-culture system of DLD-1 spheroids with PBMCs was again more resistant to FO than in the homotypic models. Although no benefit of Cetuximab addition to FO was observed in homotypic DLD-1 spheroid and PBMC cultures, less induction of resistance was observed in the co-culture system for FOC compared to FO, resulting in a significant benefit of Cetuximab (p = 0.030). Besides resistance, a chemo-sensitizing effect to FI was induced by the addition of immune cells to tumor cell line spheroids. Here, the addition of Cetuximab resulted in a significantly increased resistance of the co-culture system to FIC (Fig. 2B, p = 0.005) .
The well-documented modulating influence of different immunologic cell types on the therapeutic susceptibility of tumor cells (Katz and Shaked, 2014; Klemm and Joyce, 2014; Yang et al., 2015) was reflected in the co-cultured experiments with homotypic tumor cell line spheroids and PMBCs from healthy donors. While a major role has been described for TILs, TAMs and unconventional lymphocytes characterized by intensive reciprocal interactions with the cancer cells, freshly isolated PBMCs from healthy donors although not able to fully imitate the tumor-host relationship were able to recapture this influence on treatment response. On the other hand, the co-culture model of tumor cell line spheroids with PBMCs was still more resistant to FO therapy than observed clinically in chemo-naïve CRC patients, which allows only a limited accuracy in deducing clinical response to drug treatment. This was further supported by the fact that phenotype and functionality are reported to be highly different between PBMCs and TILs (Santin et al., 2001) . Although a ratio of 1:1 was used between tumor cells and PBMCs in the co-culture experiments, the fact that the PBMCs were not integrated into the spheroid in a large quantity reflects the reduced number of immune cells described in primary colon cancer tissues (Pernot et al., 2014) and is further reflected by the immunoscore (Galon et al., 2014) . Careful considerations are therefore necessary in the choice for and the implementation of the appropriate preclinical model in cell-based immune assays, which are widely used in both academic and pharmaceutical research.
The heterotypic tumor cell line spheroid model of tumor cell lines co-cultured with fibroblasts isolated from primary human CRC tissue samples
Heterotypic tumor cell line spheroids were generated by coculturing the Caco-2 tumor cells with primary human cancer associated fibroblasts of colorectal origin during spheroid formation. The introduction of CAFs resulted in more compact spheroids ( Fig. 1C and D) when considering the large cell size of primary fibroblasts. Homotypic Caco-2 tumor spheroids showed a similar response to treatment compared to earlier experiments. FO inhibited cellular viability significantly more than FI and the effect of both therapies could be improved upon by the addition of Cetuximab in both cases ( Figs. 2A and 3) . Contrary to the results of PBMC suspension cultures, spheroids consisting of tumorassociated fibroblasts on the other hand were almost completely resistant to treatment.
Similar to the observations made in the co-culture experiments with homotypic Caco-2 tumor spheroids and PBMCs, a decreased sensitivity to FOC but not FO was observed in the heterotypic Caco-2 and CAF spheroid co-culture model when compared to the expected co-culture results. Since the fibroblast spheroids were already almost entirely resistant to FOC treatment, the observed resistance induction can to a large part be attributed to less chemosensitive Caco-2 tumor cells. Contrary to this observation, the 3D co-culture of Caco-2 cells and primary human fibroblasts of CRC origin induced a significant sensitization to FI and FIC beyond the sensitivity of the homotypic Caco-2 spheroids although the CAF spheroids were almost entirely resistant to both treatments, suggesting one or both cell types to become more susceptible to both treatments. Also, no benefit was observed by the addition of Cetuximab to both FO and FI although the homotypic Caco-2 tumor spheroids were susceptible to Cetuximab (Fig. 3) . In summary, the tumor cell line and CAF spheroid co-cultures allowed interactions between both cell types which ultimately effected the sensitivity of the spheroids to treatment.
The observed results are in line with other publications which show that the fibroblastic niche has a profound impact on the therapeutic response of tumor cells. Cell adhesion and soluble factors secreted by the fibroblasts have been described to contribute to drug resistance in cancer (e.g. Fang et al., 2014) . CAFs interact with different cell types of the tumor microenvironment on multiple levels (Huang et al., 2014; Mahale et al., 2015; Mink et al., 2010) . Their functional heterogeneity allows the CAFs to be involved in tumor cell survival, proliferation, invasion and metastasis (e.g. Herrera et al., 2013a) . Similar to the results of the co-culture experiments with homotypic tumor cell line spheroids with PBMCs, the observations made in the heterotypic spheroid model of tumor cell lines and primary human tumor associated fibroblasts of colorectal origin underline the relevance of various factors mediated by the tumor microenvironment in patient tumors, ultimately influencing treatment response. Considering the implications of both co-culture models, the interactions of a multitude of cell types which cannot be recapitulated correctly in a two-component co-culture model affect the treatment response. In addition, the inter-patient heterogeneity regarding cellular composition cannot be mimicked by co-culture models using cell lines. In order to closely recapitulate the situation in cancer patients the cancer tissue spheroid model was developed.
The cancer tissue spheroid model
Cancer tissue spheroids were generated from 16 different colorectal cancer patient samples. Depending on the tissue composition of the individual tumor, degrees of compactness varied highly between tissue spheroids. As shown in Fig. 1 , compact spheroids were generated from patient sample #15 (Fig. 1E) , while less compact spheroids were obtained from patient tumor sample #16 (Fig. 1F) . Cancer tissue spheroids obtained from 10 CRC patients were treated with standard chemotherapy and were sensitive to both FO and FI treatment, no complete drug resistance was observed in the cancer tissue spheroid model in contrast to the tumor cell line spheroid model (Fig. 4) . Mean residual metabolic activity of the spheroids was 25.5% (range: 4.55-46.25%) after FO treatment and 31.59% (range: 1.0-56.0%, FO vs FI, p = 0.360) after FI treatment. The extent of sensitivity to each treatment differed from patient to patient as reflected by the large range of results for FO and FI (Fig. 4) . No significant difference in susceptibility to FO and FI was observed for four patient cancer samples tested with the primary cancer tissue spheroid model. FI was significantly superior to FO in one patient sample and significantly less effective compared to FO in five patient samples (Fig. 4) . In contrast to the previous experiments conducted with colorectal cancer cell line spheroids, the treatment responses observed in the primary cancer tissue spheroid model allow the conclusion that the individuality of each patient tumor is reflected, if nothing else then by mimicking the cellular composition of the original tumor tissue, relevant for the overall response to drug treatment. Regarding these aspects the cancer tissue spheroid model is suitable for functional testing of biomarker-independent anti-cancer activity. Thus, molecular drugs such as therapeutic antibodies ( Fig. 5A and B) and small molecules ( Fig. 5C and D) reported as promising agents in colorectal cancer (Grünwald and Rickmann, 2014; Linnekamp et al., 2014; Rolfo et al., 2014; Tampakis et al., 2014) were also tested on individual patient samples in the cancer Fig. 5C ). The addition of Everolimus to standard CRC treatment options did not improve treatment response in vitro (sample #14, Fig. 5D ). The patient-derived cancer tissue spheroid model was developed to simulate the tumor microenvironment of human solid cancers by retaining the cellular composition of the patient tumor without selection of any specific cell type. The result obtained with the tumor tissue spheroid model, especially the comparable overall treatment responses to FO and FI are similar to data seen in clinical trials (Tournigand et al., 2004; Colucci et al., 2005) . Mimicking the impact of the tumor microenvironment on drug response with this model allows a more effective drug development process by identifying promising drug candidates for clinical investigation in early drug development phases. Also, functional drug testing with the cancer tissue spheroid model has the potential to represent an alternative to companion diagnostics for targeted therapies, thus simplifying patient stratification by merging different diagnostic tests into one functional analysis. Despite this advantage, the cancer tissue spheroid model has limitations. Although a number of micro-environmental interactions can be recapitulated, an intact human capillary network is missing which is required for the development and testing of anti-angiogenic drugs. Moreover, drug screening requires a large number of patient tumors to be tested to compensate for the inter-patient heterogeneity in regard to treatment response which in turn requires a lot more time for tumor sample recruitment compared to tumor cell line models.
Conclusions
Clinically relevant and validated preclinical models that allow reliable deductions to clinical response represent an unmet need in early drug development. These models should simulate human tumor biology, predict clinical outcome and thus have the ability to identify the most promising treatment option. Engineering the ideal biomimetic preclinical test system is very challenging, the human tumor microenvironment and in this context its influence on treatment response is particularly difficult to reproduce. The comparison of different 3D in vitro models reported in this study revealed the cancer tissue spheroid model to be superior to homotypic and co-culture spheroid models using tumor cell lines regarding comparability to clinical efficacy of the drug combinations. The cancer tissue spheroids directly prepared from patient tumors closely resemble the human tumor stroma signature. In more detail, the human cancer tissue spheroid model is superior to the gold standard in oncological drug testing, the subcutaneous xenograft mouse model, concerning inter-species difference, tumor heterogeneity (which is lost in the mouse model) and proliferation activity (which is unnaturally high in the mouse model). On the other hand, the missing vascular system, the heterogeneity of drug efficacy from patient to patient as well as tumor sample acquisition difficulties among other factors limit wide-spread practical application of the system. Thus, the tumor tissue spheroid model can be used in small cohorts for the evaluation of drug candidates in later stages of preclinical drug screening supplementary to in vivo preclinical animal experiments, fine-tuning the drug development process before transfer to clinical investigation. For applications in earlier development phases, tumor cell line spheroid models either homotypic or in co-culture settings might be the preferable choice due to easier reproducibility, less inter-experiment variability and easy access to most of the established cell lines. Also, one of the present limitations of the heterotypic models presented here is the difficulty in determining the impact of treatment on each cell type individually out of a cell mixture in the spheroid. FACS analysis has its limitations in this context because a large quantity of cells is required and a standardized high-throughput implementation is difficult. Cell sorting with magnetic beads or antibodies might be a preferable method, ideally implemented using negative selection of the relevant cell type. In conclusion, although further technical optimization is required, the implementation of spheroid models with different complexity in early drug discovery linked with the correct choice of model for the experiments represents a key technology for improving the drug screening process (Table 4) .
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